Retatrutide and Type 1 Diabetes: Evidence, Risks, and UK Guidance
Retatrutide and type 1 diabetes is an emerging area of scientific interest, though the evidence base remains at a very early stage. Retatrutide is an investigational triple receptor agonist developed by Eli Lilly, targeting GLP-1, GIP, and glucagon receptors simultaneously. Whilst Phase 2 trials have demonstrated significant metabolic effects in adults with obesity and type 2 diabetes, no published randomised controlled trials have included people with type 1 diabetes. This article outlines what is currently known, the potential risks, the UK regulatory position, and how to have informed conversations with your diabetes care team.
Summary: Retatrutide has not been studied in type 1 diabetes clinical trials and is
Please visit the relevant website here for information about how to check the registration status of the pharmacy and the superintendent pharmacist.
Phuong Nguyen (2204151)
Bolt Healthcare Ltd
team@boltpharmacy.co.uk
Bolt Pharmacy, Unit 3C, Frontier Park, Blackburn, Lancashire, BB1 3AL
